Haleon plc
HLNHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHaleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa,. The $38.49B market capitalization puts HLN squarely in large-cap range for its industry. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Market Cap
$38.49B
Beta
0.25
P/E (TTM)
17.40
P/E (Fwd)
14.25
EPS (TTM)
$0.50
EPS (Fwd)
$0.61
ROE
10.3%
ROA
4.7%
Cash
$1.35B
Total Debt
$8.63B
Free CF
$1.40B
52W Change
-20.4%
Annual Financials
Cash vs Debt
On the balance sheet, HLN has $1.35B in cash with $8.63B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $1.40B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 10.3%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.7% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $9.54B to $11.03B.
With a beta below 0.7, Haleon plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Haleon plc carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HLN.